暂无数据
产品名称
起订量
单价(含增值税)
库存(PCS)
起订数量
产品简介
| 靶标 | DCAF15 |
| 宿主 | Rabbit |
| 稀释比例 | WB 1:1000-3000. |
| Gene ID | 90379 |
| 保存 | Store at -20°C. Avoid freeze / thaw cycles. |
| Swiss Prot | Q66K64 |
| 蛋白分子量 | 66kDa |
| 储存液 | Buffer: PBS with 0.03% Proclin300, 50% glycerol, pH7.3. |
| 免疫原 | A synthetic peptide of human DCAF15 |
| 亚型 | IgG |
| 纯化方法 | Affinity purification |
| 背景资料 | Substrate-recognition component of the DCX(DCAF15) complex, a cullin-4-RING E3 ubiquitin-protein ligase complex that mediates ubiquitination and degradation of target proteins (PubMed:16949367, PubMed:31452512). The DCX(DCAF15) complex acts as a regulator of the natural killer (NK) cells effector functions, possibly by mediating ubiquitination and degradation of cohesin subunits SMC1A and SMC3 (PubMed:31452512). May play a role in the activation of antigen-presenting cells (APC) and their interaction with NK cells (PubMed:31452512).Binding of aryl sulfonamide anticancer drugs, such as indisulam (E7070) or E7820, change the substrate specificity of the DCX(DCAF15) complex, leading to promote ubiquitination and degradation of splicing factor RBM39 (PubMed:28437394, PubMed:28302793, PubMed:31693891, PubMed:31452512). RBM39 degradation results in splicing defects and death in cancer cell lines (PubMed:28437394, PubMed:28302793, PubMed:31693891). Aryl sulfonamide anticancer drugs change the substrate specificity of DCAF15 by acting as a molecular glue that promotes binding between DCAF15 and weak affinity interactor RBM39 (PubMed:31686031, PubMed:31819272). Aryl sulfonamide anticancer drugs also promote ubiquitination and degradation of RBM23 and PRPF39 (PubMed:31693891, PubMed:31626998, PubMed:31686031). |
| Public Immunogen Range | 310-360/600aa |
| 克隆类型 | Polyclonal Antibody |
| 交叉反应 | Human |
| 应用 | WB |
| 规格 | 50ul100ul |
注意：
1.本产品仅供科研使用。请勿用于医药、临床诊断或治疗，食品及化妆品等用途。请勿存放于普通住宅区。
2.为了您的安全和健康，请穿好实验服并佩戴一次性手套和口罩操作。
暂无数据
我要询价
*联系方式：
(可以是QQ、MSN、电子邮箱、电话等，您的联系方式不会被公开)
*内容：
